

## Originalbeiträge in Fachzeitschriften (peer-reviewed)

Grössmann N, **Wolf S**, Rothschedl E, Wild C. 12-years of European cancer drug approval – a systematic investigation of the “magnitude of clinical benefit”. *Annals of Oncology*. 2020. Submitted.

Grössmann N, Robausch M, Willenbacher W, **Wolf S**, Simon J, Wild C. “Magnitude of clinical benefit” of solid tumour drugs and their real-world application in the Austrian health care setting. *Journal of Cancer Policy*. 2020, 25, 100235.

**Wolf S**, Winkler R. A systematic Analysis of Evaluation Methods for Inpatient Children and Adolescents Rehabilitation Programs. *Klin Padiatr*. 2020;232(4):187-196. English. doi: 10.1055/a-1177-1115.

**Wolf S**, Zechmeister-Koss I, Grössmann N, & Wild, C. Evaluating options for decision making on costly hospital drugs in Austria. *International Journal of Technology Assessment in Health Care*. 2020, 36(3), 277-284. doi:10.1017/S0266462320000276.

Stanak M, **Wolf S**, Jagoš H, Zebenholzer K. The impact of external trigeminal nerve stimulator (e-TNS) on prevention and acute treatment of episodic and chronic migraine: A systematic review. *J Neurol Sci*. 2020,412:116725. doi: 10.1016/j.jns.2020.116725.

Grössmann N, **Wolf S**, Rosian R, Wild C: Pre-reimbursement: Early assessment for coverage decisions. *Wiener Medizinische Wochenschrift* 2019; 169:11-12.

Zechmeister-Koss I, Stanak M, **Wolf S**: The Status of Health Economic Analyses within decision making in Austria. *Wiener Medizinische Wochenschrift* 2019; 169:11-12.

**Wolf S**, Fischer S: Systematische Übersichtsarbeit: Aussagekraft und Übertragbarkeit der Ergebnisse gesundheitsökonomischer Evaluationen zum perkutanen Aortenklappenersatz. *Wiener Medizinische Wochenschrift* 2018; 168:11-12.

Kloos RQH, van Litsenburg RRL, **Wolf S**, et al. A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2018;e27458

Grössmann N, Del Paggio J C, **Wolf S**, Sullivan R, Booth C M, Rosian K, Emprechtlinger R, Wild C: Five years of EMA-approved systemic cancer therapies for solid tumours – a comparison of two thresholds for meaningful clinical benefit. *European Journal of Cancer*. 2017; 82:66-71.